Terms: = Pancreatic cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Treatment
15 results:
1. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the keap1/NRF2 axis in pancreatic cancer.
Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
[TBL] [Abstract] [Full Text] [Related]
2. Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells.
Wang Z; Li W; Wang X; Zhu Q; Liu L; Qiu S; Zou L; Liu K; Li G; Miao H; Yang Y; Jiang C; Liu Y; Shao R; Wang X; Liu Y
Chin Med J (Engl); 2023 Sep; 136(18):2210-2220. PubMed ID: 37488674
[TBL] [Abstract] [Full Text] [Related]
3. UBR7 inhibits HCC tumorigenesis by targeting keap1/Nrf2/Bach1/HK2 and glycolysis.
Zhao L; Kang M; Liu X; Wang Z; Wang Y; Chen H; Liu W; Liu S; Li B; Li C; Chang A; Tang B
J Exp Clin Cancer Res; 2022 Nov; 41(1):330. PubMed ID: 36419136
[TBL] [Abstract] [Full Text] [Related]
4. Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective study.
Kunimasa K; Sugimoto N; Kawamura T; Yamasaki T; Honma K; Nagata S; Kukita Y; Fujisawa F; Inoue T; Yamaguchi Y; Kitasaka M; Wakamatsu T; Yamai T; Yamamoto S; Hayashi T; Inoue T; Tamiya M; Imamura F; Nishimura K; Nishino K
Thorac Cancer; 2022 Nov; 13(21):2970-2977. PubMed ID: 36100256
[TBL] [Abstract] [Full Text] [Related]
5. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer.
Yang PW; Xu PL; Cheng CS; Jiao JY; Wu Y; Dong S; Xie J; Zhu XY
J Ethnopharmacol; 2022 Oct; 297():115516. PubMed ID: 35817247
[TBL] [Abstract] [Full Text] [Related]
6. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in pancreatic cancer.
Wang X; Li Y; Li Z; Lin S; Wang H; Sun J; Lan C; Wu L; Sun D; Huang C; Singh PK; Hempel N; Trebak M; DeNicola GM; Hao J; Yang S
Cancer Res; 2022 Jun; 82(12):2254-2268. PubMed ID: 35413105
[TBL] [Abstract] [Full Text] [Related]
7. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
Chen J; Jiang S; Shao H; Li B; Ji T; Staiculescu D; He J; Zhao J; Cai L; Liang X; Xu J; Cai X
Sci China Life Sci; 2022 Oct; 65(10):1998-2016. PubMed ID: 35380342
[TBL] [Abstract] [Full Text] [Related]
8. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
9. Overcoming hypoxia-induced resistance of pancreatic and lung tumor cells by disrupting the PERK-NRF2-HIF-axis.
Küper A; Baumann J; Göpelt K; Baumann M; Sänger C; Metzen E; Kranz P; Brockmeier U
Cell Death Dis; 2021 Jan; 12(1):82. PubMed ID: 33441543
[TBL] [Abstract] [Full Text] [Related]
10. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Pandey A; Stawiski EW; Durinck S; Gowda H; Goldstein LD; Barbhuiya MA; Schröder MS; Sreenivasamurthy SK; Kim SW; Phalke S; Suryamohan K; Lee K; Chakraborty P; Kode V; Shi X; Chatterjee A; Datta K; Khan AA; Subbannayya T; Wang J; Chaudhuri S; Gupta S; Shrivastav BR; Jaiswal BS; Poojary SS; Bhunia S; Garcia P; Bizama C; Rosa L; Kwon W; Kim H; Han Y; Yadav TD; Ramprasad VL; Chaudhuri A; Modrusan Z; Roa JC; Tiwari PK; Jang JY; Seshagiri S
Nat Commun; 2020 Aug; 11(1):4225. PubMed ID: 32839463
[TBL] [Abstract] [Full Text] [Related]
11. The Genomic Landscape of
Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
[TBL] [Abstract] [Full Text] [Related]
12. Nrf2 in cancers: A double-edged sword.
Wu S; Lu H; Bai Y
Cancer Med; 2019 May; 8(5):2252-2267. PubMed ID: 30929309
[TBL] [Abstract] [Full Text] [Related]
13. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to keap1.
Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
[TBL] [Abstract] [Full Text] [Related]
14. lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141.
Wu L; Pan C; Wei X; Shi Y; Zheng J; Lin X; Shi L
Cell Commun Signal; 2018 Aug; 16(1):47. PubMed ID: 30119680
[TBL] [Abstract] [Full Text] [Related]
15. Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to keap1.
Arora R; Sawney S; Saini V; Steffi C; Tiwari M; Saluja D
Mol Cancer; 2016 Oct; 15(1):64. PubMed ID: 27756327
[TBL] [Abstract] [Full Text] [Related]
